Source:http://linkedlifedata.com/resource/pubmed/id/11985287
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2002-5-1
|
pubmed:abstractText |
In this open, 30-day trial, the pharmacokinetics, safety and tolerability of a combination therapy of risperidone (4 or 6 mg/day)and fluoxetine (20mg/day from day 6) were evaluated in 11 psychotic inpatients. CYP2D6 genotyping revealed that 3 and 8 patients were poor metabolizers (PMs) and extensive metabolizers (EMs) of debrisoquine, respectively. The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively. The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively. In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)). Ten of the 11 patients showed a clinical improvement (reduction of 20% or more in total PANSS score and 70% on the mean MADRS score compared to baseline). The severity and incidence of extrapyramidal symptoms and adverse events did not significantly increase when fluoxetine was added.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antidepressive Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 CYP2D6,
http://linkedlifedata.com/resource/pubmed/chemical/Fluoxetine,
http://linkedlifedata.com/resource/pubmed/chemical/Risperidone
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0176-3679
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
50-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11985287-Adolescent,
pubmed-meshheading:11985287-Adult,
pubmed-meshheading:11985287-Aged,
pubmed-meshheading:11985287-Antidepressive Agents, Second-Generation,
pubmed-meshheading:11985287-Antipsychotic Agents,
pubmed-meshheading:11985287-Area Under Curve,
pubmed-meshheading:11985287-Cytochrome P-450 CYP2D6,
pubmed-meshheading:11985287-Drug Interactions,
pubmed-meshheading:11985287-Female,
pubmed-meshheading:11985287-Fluoxetine,
pubmed-meshheading:11985287-Hemodynamics,
pubmed-meshheading:11985287-Humans,
pubmed-meshheading:11985287-Male,
pubmed-meshheading:11985287-Middle Aged,
pubmed-meshheading:11985287-Psychiatric Status Rating Scales,
pubmed-meshheading:11985287-Psychotic Disorders,
pubmed-meshheading:11985287-Risperidone,
pubmed-meshheading:11985287-Switzerland
|
pubmed:year |
2002
|
pubmed:articleTitle |
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.
|
pubmed:affiliation |
Dépatrement universitaire de psychiatrie adulte, Site de Cery, Pirlly-Lausanne, Switzerland. guido.bondolfi@hcuge.ch
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|